Sun Pharma posts Q1 profit on strong US sales

Tags: Companies
Sun Pharmaceutical Industries Ltd, India's largest drugmaker by market value, reported a better-than-expected first-quarter profit, reflecting higher sales in its largest market, the United States.

April-June net profit was 13.91 billion rupees ($227.73 million), compared with a net loss of 12.76 billion rupees a year earlier. The prior-year period included a 25.17 billion rupee provision for settlement of a patent infringement litigation.

Analysts on average had expected a profit of 12.85 billion rupees, according to data compiled by Thomson Reuters.

Net sales rose 12 percent to 39.36 billion rupees, while sales in the United States, from where the company makes more than half its revenue, advanced 7 percent.

Sun Pharma is in the process of gaining regulatory approvals for its $3.2 billion acquisition of loss-making rival Ranbaxy Laboratories Ltd from Japan's Daiichi Sankyo Ltd and expects to close the deal by December.

The company has got approvals for the deal from anti-competition authorities in all applicable markets excluding India and the United States, Sun Pharma said in a statement late on Tuesday.


  • Banks have been reluctant to transmit RBI policy rate cuts to borrowers

    Banks have been slow in passing the benefit of repo rate cuts by the central bank to their borrowers.


Stay informed on our latest news!


Sarthak Raychaudhuri

vice-president, HR, Asia South Whirlpool of India

GV Nageswara Rao

MD & CEO, IDBI Federal Life

Timothy Moe

Goldman Sachs


Arun Nigavekar

Ranking of higher education institutions

Given the massive popularity and growing influence of world university ...

Rajgopal Nidamboor

The pursuit of serene stillness

It may sound strange — that every change in the ...

Dharmendra Khandal

How positive intervention can go a long way

Ten years ago, Sariska tiger reserve declared that there were ...


William D. Green

Chairman & CEO, Accenture